Personalized medicine approach for treating cognitive loss
AssigneeUniversity of North Texas Health Science Center at Forth Worth
InventorSid E. O'Bryant
Life of this patent
Estimating the term…
Abstract
The present invention includes methods for selecting a therapy for improved cognition as well as prevention of cognitive loss/dysfunction using one or more endophenotypes comprising: obtaining a sample from a subject; measuring biomarkers that differentiate between an inflammatory, a metabolic, a neurotrophic, and a depressive endophenotype; and selecting a course of treatment for the subject based on whether the subject is scored as having a high or a low endophenotype for one or more of the inflammatory, a metabolic, a neurotrophic, and a depressive endophenotypes.
Claims8
A method for treating a human subject with Alzheimer's Disease having a high proinflammatory endophenotype, the method comprising:
- obtaining a blood sample from the human subject with Alzheimer's disease;
- measuring the protein expression levels of tumor necrosis factor-alpha (TNFα), IL-5, IL-6, and C-reactive protein (CRP) biomarkers in the blood sample;
- applying an algorithm to the measured protein expression levels, the algorithm generating an endophenotype score based on a comparison of the measured protein expression levels to reference levels;
- identifying the human subject with Alzheimer's Disease as having a high proinflammatory endophenotype profile based on the endophenotype score;
- and
- administering an anti-inflammatory drug treatment to the identified human subject;
- wherein the algorithm is selected from a machine learning algorithm, a clustering algorithm, and a combination thereof.
Dependencies are inferred from the claim text.